Investigational drug · Phase 2
EGEN-5784
Also called: Genetically Engineered Porcine Liver, xenogeneic porcine liver, EGEN-5784 liver
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute on Chronic Liver Failure (ACLF), Hepatic Encephalopathy (HE).
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "EGEN-5784"
First trial start
2026
Oct 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EGEN-5784", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute on Chronic Liver Failure (ACLF)
- Hepatic Encephalopathy (HE)
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "EGEN-5784" as an intervention, largest first.
- RENEW: Study of Porcine Liver Support in Participants With Acute-on-Chronic Liver FailureNot yet recruiting
eGenesis, INCIndustry
NCT07429838 · 20 participants (planned) · Start Oct 2026 · Primary completion Dec 2027
Drug: EGEN-5784 (genetically engineered porcine liver) · For: Acute on Chronic Liver Failure (ACLF); Hepatic Encephalopathy (HE)
Sites: St Louis, Missouri; Madison, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
- Simultaneous quantification of native human and transgenic porcine liver function in a decedent model of extracorporeal cross-circulation.
Shaked A, McRae MP, Imperial JC, et al. · Am J Transplant 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.